These biotechs are soaring today 🦅

Plus check out this earnings winner                                                                                                                                                                                                                                                                                                                                                                                                                 Good morning, 360! Here are our TOP investing ideas today — and make sure to see out Spotlight feature for two important deadlines TODAY. Have a great week, 360! IMRN - Up over 65% after FDA removes clinical hold BLCM - Up over 75% in pre-market after Baker Bros. Advisors report 19.99% stake ZS - Up over 20% after increasing earnings guidance ⏰ATTN: DOUBLE Deadlines Today!⏰ 📚Wall Street Bookie – Trial Offer ends📚 Jeff Wants You to Claim His #1 Strategy of All-Time. [Only $997 $47 Today!→ Deal Expires At Midnight.]( AND… 🤖 NEW: The Great Tech Reckoning 🤖 The recent bank and tech shakeout is the prime environment for a phenomenon Jeff has dubbed…the Gamma Trigger! Tuesday night (May 9th at 8pm EST) Jeff will reveal how the Gamma Trigger works, demonstrating exactly how he’s using it to snatch up juicy winners! [🗓️ RESERVE YOUR SEAT BY MIDNIGHT MAY 8th 🗓️]( IMRN - Up over 65% after FDA removes clinical hold Immuron (IMRN), a clinical stage biotech company, is up over 65% in the pre-market after the FDA removed a clinical hold to start the trial of the company’s bacterial diarrhea drug. This paves the way for the company to begin trials for its New Campylobacter ETEC Therapeutic. $3 has acted as support so far in the pre-market and will be an important level to watch this morning. Above it, targets to the upside are at $3.20, $3.40 and the pre-market high at $3.61. Beyond that, targets are $4, $4.20 and $5. Below $3, there is potential support at $2.80, $2.60, $2.20 and a gap to fill at $1.87. BLCM - Up over 75% in pre-market after Baker Bros. Advisors report 19.99% stake Bellicum Pharmaceuticals (BLCM) reported that Baker Bros. had filed a 19.99% stake in the company. The biotech, who’s market cap was just $3.4 million at the previous close soared 75% in pre-market on the news. Baker Brothers is a private hedge fund managing over[$25 billion in assets](. $0.70 was resistance in the pre-market which became potential support. Above it, targets to the upside are at $0.80, $0.90 and then the $1 psychological level. Beyond that, $1.10, $1.20 and $1.40 come into play. Below $0.70, there is potential support at $0.63, $0.60 and $0.53, with a gap to fill at $0.40. ZS - Up over 20% after increasing earnings guidance Zscalar (ZS) operates as a cloud security company worldwide. The company announced this morning that it expects to report Q3 results above previous guidance and raised its guidance for the Full-Year. ZS raised its preliminary Q3 revenue guidance from $396-$398 million to $415-$419 million. The company now expects full year non-GAAP income from $220 to $224 million vs $213-$215 million. The $111 area has been resistance so far in the pre-market and will be an important level to watch. Above it, targets to the upside are at $114, $118 and $122. Below $111, there is potential support at $107.50, $104.50, and then the $100 level. Economic Calendar (EST) 10:00am Wholesale Inventories 12:30pm Investor Movement Index No Fed Speakers Schedule Earnings for Today (After Market) ACAD, ACM, ADEA, ADTN, AEL, AESI, AKYA, ALTO, AMEH, APTO, ARGO, ARIS, ARKO, ASUR, ATIP, ATRA, AVIR, AVTA, BAK, BHF, BKD, BODY, BRBR, BRDG, BRT, BWMN, BWXT, CAPL, CBT, CENX, CERT, CHMI, CHRS, CMBM, CRVS, DCGO, DDD, DHC, DO, DOOR, DRQ, DRRX, DSP, DVA, DVN, DZSI, EFC, ENTA, EQRX, ERO, ESTA, EVER, FAT, FGEN, FLL, FN, FOA, FTK, GBDC, GHLD, GNSS, HBM, HHC, HI, HIMS, HLIO, HLIT, HNRG, HPP, ICUI, IFF, III, IIPR, INTA, IPAR, ISPO, ISSC, JELD, KARO, KFRC, KMPR, LAND, LCID, LEU, LMB, MCK, MEDS, MRC, MRDB, MRMD, MRVI, MTRX, MWA, NEO, NEWT, NINE, NMFC, NNI, OCUL, OPRT, ORN, PAR, PAY, PGNY, PLTR, PR, PRAA, PRI, PTVE, PYPL, QNRX, RBOT, RC, REPX, ROVR, RVMD, SEMR, SES, SHLS, SKYT, SLDP, SNDX, SU, SVC, SWAV, SWKS, TALO, TASK, TBPH, TCMD, TCX, TDW, TMCI, TREX, TRHC, TRUE, TSLX, UFCS, VECO, VMD, VTR, VTS, WDC, WPRT, WTRG, XNCR, YMAB, ZYME Top Headlines RKLB Rocket Lab Prepares for First of Two Launches to Deploy Storm Monitoring Constellation for NASA NYC pension funds lose $30M in SVB collapse, data shows NY Post SGHT Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry BGNE - BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China BRKB Warren Buffett’s Berkshire Hathaway Inc BRK on Saturday said its first-quarter profit totaled $35.5 billion, reflecting gains from common stocks such as Apple Inc, while higher income from investments bolstered operating profit. The Omaha, Nebraska-based company said it also repurchased $4.4 billion of its own stock in the quarter. ABBV AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week® DBD Diebold Nixdorf, Incorporated Receives Continued Listing Standard Notice from NYSE; Company Further Extends Exchange Offer with Respect to its Outstanding 8.50% Senior Notes Due 2024 IMUX Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action HSIC Henry Schein Acquires Regional Health Care Group, a Medical Distributor Serving the Australia and New Zealand Region RKLB Rocket Lab Successfully Launches First Batch of TROPICS Satellites for NASA VEON VEON Receives Nasdaq Notice on Delayed Filing of 2022 Annual Report JETS Biden plans to bolster US airline consumer protections IMRN Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation AES AES Outlines Long-Term Strategy for Growth in Renewables US Utilities, While Executing on Intent to Exit Coal by Year-End 2025 KALV: KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency Angioedema Workshop SPRC SciSparc’s Drug Discovery Joint Venture MitoCareX Bio Successfully Developed its Core Algorithm to allow suitable Modeling of Human Mitochondrial Carriers for Accelerating its Cancer Drug Discovery Program WELL: Welltower Announces Proposed Private Placement of $750 Million of Exchangeable Senior Notes HAYW Hayward Holdings Announces Secondary Offering of 21,000,000 Shares of Common Stock by Selling Stockholders MNK Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at Digestive Disease Week (DDW) 2023 DNA: Ginkgo Bioworks Partners with Boehringer Ingelheim to Develop Breakthrough Therapies for Hard- to-Treat Diseases ACST: Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025 AMLI American Lithium Receives First of 3 Drill Permits to Commence Additional Development and Discovery Drilling at and around Falchani Peru SCTL: Societal CDMO Selected by Xequel Bio to Provide CDMO Services to Support Ongoing Clinical Development of iNexin™ MCRB Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting ODV: Osisko Development Announces Signing of Process Charter and Joint Information Requirements Table for Cariboo Gold Project MIST: Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate ARKO: ARKO Corp. Announces the Extension of Oak Street Commitment for up to $1.5 Billion and Announces a Credit Line Increase to $800 Million and Extension of Maturity LXU: LSB Industries Announces Stock Repurchase Program Authorization of up to $150 Million BRKR: Bruker Announces Acquisition of ZONTAL to Advance the Digital Laboratory Transformation and Integrated Biopharma Data Solutions BRTX: BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in theCompany’s Phase 2 Clinical Trial ACOR: Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China To Your Success! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [(. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services. However, RagingBull. com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. RagingBull .com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. [tw]( Update your email preferences or unsubscribe [here]( © 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States [[beehiiv logo]Powered by beehiiv](